Relapsing MS patients fared better after switch to Kesimpta | Multiple Sclerosis News Today
People with relapsing MS who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta.
Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
People with relapsing MS who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta.
Multiple treatment transitions in patients with NMOSD are associated with increased neurological harm, including increased relapse risk and disease progression.
Analyses of protein levels in the blood can be used to identify groups of MS patients with distinct clinical features, which may improve care.
The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.
The European Commission has approved Briumvi to treat people with relapsing forms of MS who have active disease.